文献速递淋巴瘤

剂量调整EPOCH-R风险适应治疗成人初治伯基特淋巴瘤的多中心研究

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
PubMed 文献 · J Clin Oncol · 2020-05-26

这项多中心风险适应研究纳入113例未经治疗的成人伯基特淋巴瘤患者,低危接受3周期DA-EPOCH-R无中枢预防,高危接受6周期并鞘内中枢预防。中位随访58.7个月,无事件生存率84.5%、总生存率87.0%,低危与高危无事件生存率分别为100%和82.1%,治疗耐受性良好。

要点

  • 低危患者接受3周期DA-EPOCH-R且不做中枢预防,高危患者接受6周期并鞘内中枢预防。
  • 中位随访58.7个月时,无事件生存率84.5%、总生存率87.0%。
  • 脑脊液受累组早期毒性相关死亡或治疗失败风险最高。

核心结论

  • 风险适应DA-EPOCH-R治疗对成人伯基特淋巴瘤有效,不受年龄或HIV状态影响,且耐受性良好。
  • 需要改进针对脑脊液受累成人患者的治疗策略。

研究设计与样本

  • 多中心风险适应研究,2010年至2017年在22个中心入组113例未经治疗的成人伯基特淋巴瘤患者,98例(87%)为高危。
  • 低危患者接受3周期DA-EPOCH-R且不做中枢预防,高危患者接受6周期并鞘内中枢预防,脑膜受累者延长鞘内治疗。
  • 主要终点为无事件生存率(EFS),次要终点为毒性以及EFS和总生存率(OS)的预测因素。

主要发现

  • 中位年龄49岁(范围18-86岁),62%的患者≥40岁;29例(26%)有骨髓和/或脑脊液受累,28例(25%)HIV阳性。
  • 中位随访58.7个月时,EFS为84.5%、OS为87.0%;低危患者EFS为100%,高危患者EFS为82.1%。
  • 治疗在各年龄组、HIV状态和国际预后指数风险组间疗效相同。
  • 脑脊液受累识别出早期毒性相关死亡或治疗失败风险最高的组。
  • 治疗期间发生5例(4%)治疗相关死亡;发热性中性粒细胞减少发生于16%的周期,肿瘤溶解综合征罕见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) may obviate the need for highly dose-intensive chemotherapy in adults with Burkitt lymphoma. METHODS: We conducted a multicenter risk-adapted study of DA-EPOCH-R in untreated adult Burkitt lymphoma. Low-risk patients received three cycles without CNS prophylaxis, and high-risk patients received six cycles with intrathecal CNS prophylaxis or extended intrathecal treatment if leptomeninges were involved. The primary endpoint was event-free survival (EFS), and secondary endpoints were toxicity and predictors of EFS and overall survival (OS). RESULTS: Between 2010 and 2017, 113 patients were enrolled across 22 centers, and 98 (87%) were high risk. The median age was 49 (range, 18-86) years, and 62% were ≥ 40 years. Bone marrow and/or CSF was involved in 29 (26%) of patients, and 28 (25%) were HIV positive. At a median follow-up of 58.7 months, EFS and OS were 84.5% and 87.0%, respectively, and EFS was 100% and 82.1% in low- and high-risk patients. Therapy was equally effective across age groups, HIV status, and International Prognostic Index risk groups. Involvement of the CSF identified the group at greatest risk for early toxicity-related death or treatment failure. Five treatment-related deaths (4%) occurred during therapy. Febrile neutropenia occurred in 16% of cycles, and tumor lysis syndrome was rare. CONCLUSION: Risk-adapted DA-EPOCH-R therapy is effective in adult Burkitt lymphoma regardless of age or HIV status and was well tolerated. Improved therapeutic strategies for adults with CSF involvement are needed (funded by the National Cancer Institute; ClinicalTrials.gov identifier: NCT01092182).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol. 2020. PMID: 32453640. doi:10.1200/JCO.20.00303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。